These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30196384)

  • 1. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
    Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
    Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
    Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
    Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice.
    Rothwell WT; Bell P; Richman LK; Limberis MP; Tretiakova AP; Li M; Wilson JM
    Cancer Res; 2018 Nov; 78(21):6171-6182. PubMed ID: 30154145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.
    Baker JH; Lindquist KE; Huxham LA; Kyle AH; Sy JT; Minchinton AI
    Clin Cancer Res; 2008 Apr; 14(7):2171-9. PubMed ID: 18381959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    Lee JY; Joo HS; Choi HJ; Jin S; Kim HY; Jeong GY; An HW; Park MK; Lee SE; Kim WS; Son T; Min KW; Oh YH; Kong G
    J Natl Cancer Inst; 2019 Jun; 111(6):609-619. PubMed ID: 30265336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer.
    Silvestri VL; Tran AD; Chung M; Chung N; Gril B; Robinson C; Difilippantonio S; Wei D; Kruhlak MJ; Peer CJ; Figg WD; Khan I; Steeg PS
    Neuro Oncol; 2024 Jun; 26(6):1067-1082. PubMed ID: 38363979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
    Bloom MJ; Jarrett AM; Triplett TA; Syed AK; Davis T; Yankeelov TE; Sorace AG
    BMC Cancer; 2020 Apr; 20(1):359. PubMed ID: 32345237
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
    Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
    PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
    Nounou MI; Adkins CE; Rubinchik E; Terrell-Hall TB; Afroz M; Vitalis T; Gabathuler R; Tian MM; Lockman PR
    Pharm Res; 2016 Dec; 33(12):2930-2942. PubMed ID: 27528392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
    Sorace AG; Quarles CC; Whisenant JG; Hanker AB; McIntyre JO; Sanchez VM; Yankeelov TE
    Breast Cancer Res Treat; 2016 Jan; 155(2):273-84. PubMed ID: 26791520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
    Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
    AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
    Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
    Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
    Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
    J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
    Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
    J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
    Arvanitis CD; Askoxylakis V; Guo Y; Datta M; Kloepper J; Ferraro GB; Bernabeu MO; Fukumura D; McDannold N; Jain RK
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8717-E8726. PubMed ID: 30150398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.